At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.
Looking for a particular SCYNEXIS, Inc. employee's phone or email?
SCYNEXIS, Inc. Questions
The SCYNEXIS, Inc. annual revenue was $9.7 million in 2026.
David Angulo is the CEO of SCYNEXIS, Inc..
50 people are employed at SCYNEXIS, Inc..
SCYNEXIS, Inc. is based in Jersey City, New Jersey.
The NAICS codes for SCYNEXIS, Inc. are [3254, 32, 54, 541, 325, 32541].
The SIC codes for SCYNEXIS, Inc. are [283, 28].
Top SCYNEXIS, Inc. Employees
-
David Angulo
Chief Executive Officer at SCYNEXIS, Inc.
Jersey City, NJ, US45+ -
Ivor MacLeod
Chief Financial Officer at SCYNEXIS, Inc.
New York, NY, US25+ -
Scott Sukenick
Chief Legal Officer at SCYNEXIS, Inc.
New York, NY, US25+ -
35+
-
Donatus Ako-Arrey
Head of Regulatory Affairs at SCYNEXIS, Inc.
Jersey City, NJ, US21 -
David Kriesel
Senior Director Medical Science Liaisons at SCYNEXIS, Inc.
San Diego, CA, US34 -
Sreeni Megati
Director, CMC at SCYNEXIS, Inc.
United States23 -
Jane Soong
Executive Director, Finance at SCYNEXIS, Inc.
New York, NY, US13
Related Companies
